Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML

Watanabe, K; Kage, H; Nagoshi, S; Toyama, K; Ohno, Y; Shinozaki-Ushiku, A; Nakazaki, K; Suzuki, H; Kurokawa, M; Nagase, T

Kage, H (corresponding author), Univ Tokyo, Dept Resp Med, Tokyo, Japan.

CASE REPORTS IN ONCOLOGICAL MEDICINE, 2020; 2020 ():

Abstract

Tyrosine kinase inhibitor (TKI) combination is expected to increase in the era of precision medicine. TKI combination may be required to treat double ......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索